| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
CAMBRIDGE, Mass., Nov. 5, 2026 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and u... |
| 28 Oct 2026 |
Form 4: Gheuens Sarah, Chief Medical Officer
Received 7,866 shares by exercise or conversion ($197K) · Sold 7,866 shares ($296K) |
| 26 Oct 2026 | 144 |
| 23 Oct 2026 |
Form 4: Gheuens Sarah, Chief Medical Officer
Received 1,489 shares by exercise or conversion ($37.2K) · Sold 1,489 shares ($55.9K) · Received 500 shares by exercise or conversion ($12.5K) · 1 more |
| 22 Oct 2026 | 144 |
| 21 Oct 2026 | 144 |
| 06 Aug 2026 |
Form 4: Gheuens Sarah, Chief Medical Officer
Sold 30,000 shares ($914K) |
| 04 Aug 2026 | 144 |
| 03 Aug 2026 | SCHEDULE 13G/A |
| 30 Jul 2026 | 10-Q |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition
CAMBRIDGE, Mass., July 30, 2026 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and ... |
| 10 Jul 2026 |
Form 4: Backstrom Jay T., Director
Received 1,447 shares as a grant or award · Exercised 1,447 Restricted stock units |
| 02 Jul 2026 | SCHEDULE 13G |
| 02 Jul 2026 |
Form 4: Gheuens Sarah, Chief Medical Officer
Received 8,375 shares by exercise or conversion · Sold 4,007 shares ($151K) |
| 01 Jul 2026 | 144 |
| 23 Jun 2026 |
Form 4: Ballal Rahul D., Director
Received 2,816 shares by exercise or conversion · Granted 2,927 Restricted stock units · Granted 14,950 Stock options (right to buy) |
Loading...